Research programme: inflammatory kinase inhibitors - Cellzome

Drug Profile

Research programme: inflammatory kinase inhibitors - Cellzome

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Cellzome
  • Developer Cellzome; GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action MTOR protein inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors; ZAP 70 protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Germany
  • 21 May 2012 Cellzome has been acquired and merged into GlaxoSmithKline
  • 15 Sep 2008 Cellzome and GlaxoSmithKline enter into alliance to discover, develop and market kinase-targeted therapeutics to treat inflammation worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top